Skip to main content

Digestive Health

0
Pipeline Programs
2
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
5 programs
FructanaseN/A1 trial
InulinaseN/A1 trial
OPTIZIOME® P³ HYDROLYZER® - WHEYN/A1 trial
Oat fiberN/A1 trial
Omeprazole 20 mgN/A1 trial
Active Trials
NCT06628869Completed30Est. Dec 2024
NCT05744700Completed60Est. Oct 2023
NCT05957185Completed24Est. Jan 2024
+2 more trials
One Biosciences
One BiosciencesFrance - Paris
1 program
Oat fiberN/A

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
BiocorpOmeprazole 20 mg
BiocorpOat fiber
BiocorpFructanase
BiocorpOPTIZIOME® P³ HYDROLYZER® - WHEY
BiocorpInulinase

Clinical Trials (5)

Total enrollment: 178 patients across 5 trials

NCT07142486BiocorpOmeprazole 20 mg

Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal

Start: Sep 2025Est. completion: Mar 20264 patients
N/ARecruiting
NCT06739941BiocorpOat fiber

Investigating the Tolerability of Oat Fiber (BG-OS) in Healthy Individuals

Start: Jan 2025Est. completion: Apr 202560 patients
N/ACompleted
NCT06628869BiocorpFructanase

The Effects of Oral Fructanase Administration on Gastrointestinal Symptoms After Inulin Challenge in Healthy Adults

Start: Nov 2024Est. completion: Dec 202430 patients
N/ACompleted
NCT05957185BiocorpOPTIZIOME® P³ HYDROLYZER® - WHEY

Effects of Microbial Protease Supplementation on Postprandial Plasma Amino Acid Concentrations and Appetite

Start: Aug 2023Est. completion: Jan 202424 patients
N/ACompleted
NCT05744700BiocorpInulinase

Safety and Tolerability Trial of Microbial Inulinase

Start: Apr 2023Est. completion: Oct 202360 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 178 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.